Thomas Martin

TL;DR: The depth of response including MRD-, long-term outcomes, and kinetics of tumor response in the IKEMA study concluded that achievement of minimal residual disease negative (MRD-) status in multiple myeloma (MM) is associated with improved progression-free survival (PFS) and overall survival (OS).

TL;DR: The data presented suggest that ZEA3 negatively modulates cytokinin responses and may function as a broad regulator of seedling development.

TL;DR: A retrospective evaluation of MRD used as part of clinical care validates MRD as an important prognostic marker in NDMM and RRMM and supports its use as an endpoint in future clinical trials as well as for clinical decision making.

TL;DR: In this article, the comparative efficacy of ciltacabtagene autoleucel (cilta-cel) versus the approved idecabtagne vicleucel(ide-cel), a CAR-positive T-cells for the treatment of patients with relapsed or refractory multiple myeloma (RRMM) who were previously treated with a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody (i.e. triple-class exposed) using matching-adjusted indirect treatment comparisons

TL;DR: CFZ can be administered to MM pts with substantial renal dysfunction and does not require dose adjustment, and Responses in relapsed and refractory MM ptsWith renal insufficiency are encouraging, and further evaluation of CFZ in renally impaired patients is ongoing.